Assessment of Serum S100A8 Levels in Rheumatoid Arthritis Patients on Infliximab
DOI:
https://doi.org/10.32947/ajps.v25i4.1266Keywords:
Rheumatoid arthritis, S100A8, CDAI, Infliximab, ESRAbstract
Background: Rheumatoid arthritis is a chronic, damaging autoimmune disease identified by systemic inflammation; it initially impacts the joints. S100A8 is a calcium-binding protein and one of the S100 protein family, which is crucial for developing multiple inflammatory diseases, especially rheumatoid arthritis.
Objective: This study aims to estimate serum S100A8 levels in rheumatoid arthritis patients receiving infliximab therapy and its effect on disease activity.
Methods: A case-controlled study was conducted on 65 rheumatoid arthritis patients receiving infliximab infusion therapy and 25 healthy individuals as control. The enzyme-linked immunosorbent assay (ELISA) was applied to determine S100A8 levels. In addition, Clinical Disease Activity Index (CDAI) scores and erythrocyte sedimentation rate (ESR) were also assessed.
Results: The current study demonstrated that the levels of S100A8 in patients with rheumatoid arthritis were significantly higher than in healthy controls, with a p-value less than 0.0001. Also, it was useful for distinguishing individuals with rheumatoid arthritis from a healthy subject, with excellent Area Under the Curve (AUC) and very high sensitivity and specificity (95.38% and 100%, respectively). Furthermore, this study shows a weak positive correlation between S100A8 and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis patients (R = 0.087, p = 0.491).
Conclusion: This study concluded that, despite taking infliximab therapy, the levels of S100A8 remained higher in rheumatoid arthritis patients when compared with controls, indicating that it could be a marker for rheumatoid arthritis disease.
References
1- Alghulami OM, Jasim GA, Jasim SY. Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023;23(2):168-79.
2- Gravallese EM, Firestein GS. Rheumatoid arthritis—common origins, divergent mechanisms. New England Journal of Medicine. 2023;388(6):529-42.
3- Farooq AO, Mohammed NH. Effect of Captopril on Toll Like Receptor Expression in Adjuvant Induced Arthritis. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2022;22(1):1-7.
4- Radu A-F, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.
5- Cerón JJ, Ortín-Bustillo A, López-Martínez MJ, Martínez-Subiela S, Eckersall PD, Tecles F, et al. S-100 proteins: basics and applications as biomarkers in animals with special focus on calgranulins (S100A8, A9, and A12). Biology. 2023;12(6):881.
6- Wu Y-y, Li X-f, Wu S, Niu X-n, Yin S-q, Huang C, et al. Role of the S100 protein family in rheumatoid arthritis. Arthritis Research & Therapy. 2022;24(1):35.
7- Blom AB, van den Bosch MH, Blaney Davidson EN, Roth J, Vogl T, van de Loo FA, et al. The alarmins S100A8 and S100A9 mediate acute pain in experimental synovitis. Arthritis Research & Therapy. 2020;22:1-15.
8- Abd Elsamea MH, Mahran SA, Badr AN, Kamal DT, Khidre TM. Evaluation of serum calprotectin level as a biomarker of disease activity in rheumatoid arthritis and osteoarthritis patients. The Egyptian Rheumatologist. 2022;44(3):185-90.
9- Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 proteins as an important regulator of macrophage inflammation. Frontiers in immunology. 2018;8:1908.
10- Dissanayake K, Jayasinghe C, Wanigasekara P, Dissanayake J, Sominanda A. Validity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients. Plos one. 2022;17(11):e0278285.
11- Paulson A, Abraham FA, Davis F, Ranji NM, Panayappan KKL. Assessment of Disease Severity in Rheumatoid Arthritis Patients Using Das28, Cdai, Raad Score and Rapid-3–A Review. International Journal of Multidisciplinary and Current Educational Research. 2021;3(2):146-8.
12- Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold LR, Feathers VL, et al. The clinical disease activity index and the routine assessment of patient index data 3 for achievement of treatment strategies. The Journal of Rheumatology. 2021;48(12):1776-83.
13- Roszkowski L, Jaszczyk B, Plebańczyk M, Ciechomska M. S100A8 and S100A12 proteins as biomarkers of high disease activity in patients with Rheumatoid Arthritis that can be regulated by epigenetic drugs. International Journal of Molecular Sciences. 2022;24(1):710.
14- Xiang Y, Zhang B, Lai X, Han K, Li J, Song L, et al. To explore the application of HMGB1, SII, S100A8/A9 and MCP-1 in the diagnosis, condition monitoring and prognosis of rheumatoid arthritis. 2022.
15- Gernert M, Schmalzing M, Tony H-P, Strunz P-P, Schwaneck EC, Fröhlich M. Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. Arthritis Research & Therapy. 2022;24(1):200.
16- Zeng J, Liu X, Liu J, Wu P, Yang L. Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: A meta-analysis. Biomarkers in Medicine. 2022;16(17):1239-49.
17- Salman NA. Assessment the Role of Erythrocyte Sedimentation Rate and C-Reactive Protein Tests For Prediction Of Rheumatoid Arthritis Activity In Misan Province. Journal Port Science Research. 2024;7(issue):8-13.
18- Diwan ZJ, Al-Marsomy WA. Evaluation of Several Hematologic and Serological Parameters in Rheumatoid Arthritis Patients. Ibn AL-Haitham Journal For Pure and Applied Sciences. 2024;37(2):128-34.
19- Mohammed TS, Maroof RE, Al-Hafidh AH. Rheumatoid Arthritis Effects on Kidney and Liver and their Correlations with CDAI. Journal of Techniques. 2022;4(Special Issue):116-22.
20- Choe J-Y, Lee CU, Kim S-K. Association between novel hematological indices and measures of disease activity in patients with rheumatoid arthritis. Medicina. 2023;59(1):117.
21- Seringec Akkececi N, Ciftcioglu M, Okyar B, Yildirim Cetin G. Relationship of immature granulocytes with disease activity in rheumatoid arthritis. International Journal of Rheumatic Diseases. 2024;27(6):e15216.
22- Movahedi M, Cesta A, Li X, Bombardier C, investigators O. Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort. Plos one. 2022;17(9):e0274264.
23- 23.Ahmad R, Zgair A. Immunological and Biological Manifestation of Rheumatoid Arthritis Patient in Iraq. Indian Journal of Forensic Medicine & Toxicology. 2021;15(4):1344-50.
24- 24.Gaballah AEA, Elsawy NA, El Gendy WM, Afifi AH, Hanafi MSM. Hematological markers and ultrasound 7-joint inflammation score as add-on tools in the assessment of inflammation in rheumatoid arthritis patients. Egyptian Rheumatology and Rehabilitation. 2022;49(1):25.
25- 25.Baillet A, Trocmé C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology. 2010;49(4):671-82.
26- 26.Huang X, Liu J, Huang W. Identification of S100A8 as a common diagnostic biomarkers and exploring potential pathogenesis for osteoarthritis and metabolic syndrome. Frontiers in Immunology. 2023;14:1185275.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sana Dhia Khalil, Wassan AbdulKarreem Abbas, Mayssaa Essam Abdulla, Mojtaba Mohammadzadeh Vazifeh
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
